A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT06508320
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
932
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza
SARS-CoV-2
Interventions
BIOLOGICAL:
mRNA-1083
Sponsor
ModernaTX, Inc.